[
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient",
    "summary": "PRINCETON - Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has accepted the supplemental biologics license application for Opdivo plus Yervoy as a potential...",
    "url": "https://finnhub.io/api/news?id=f160dff2c091d055982cc825fb879b82001e055a399dbd098b931d3148195060",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740477453,
      "headline": "U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient",
      "id": 132871043,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "PRINCETON - Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has accepted the supplemental biologics license application for Opdivo plus Yervoy as a potential...",
      "url": "https://finnhub.io/api/news?id=f160dff2c091d055982cc825fb879b82001e055a399dbd098b931d3148195060"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
    "summary": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
    "url": "https://finnhub.io/api/news?id=8d842d83f6441922524668fd84310b88e154005d92e6ffaab42931a7a420916f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740477240,
      "headline": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
      "id": 132881609,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
      "url": "https://finnhub.io/api/news?id=8d842d83f6441922524668fd84310b88e154005d92e6ffaab42931a7a420916f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb to Participate in Upcoming Investor Conferences",
    "summary": "Bristol Myers Squibb today announced that the company will participate in two upcoming investor conferences in March 2025.The company will participate in a fireside chat at the TD Cowen 45th...",
    "url": "https://finnhub.io/api/news?id=35d4bac52355331e55361b934e0e91003a2f61879d5532b25f4b5ab80d6de7fc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740466803,
      "headline": "Bristol Myers Squibb to Participate in Upcoming Investor Conferences",
      "id": 132869755,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb today announced that the company will participate in two upcoming investor conferences in March 2025.The company will participate in a fireside chat at the TD Cowen 45th...",
      "url": "https://finnhub.io/api/news?id=35d4bac52355331e55361b934e0e91003a2f61879d5532b25f4b5ab80d6de7fc"
    }
  }
]